The purpose of this study is to find out more about an investigational drug, ARI-3037MO. ARI-3037MO is being developed to see if it can help people lower LDL-C levels who have dyslipidemia. This study will compare ARI-3037MO with a placebo to see if using ARI-3037MO is better than using a placebo.

Participation could be about 35 weeks and could involve up to eight study visits. The visits are in person.

Study Site: Baylor College of Medicine
Study Doctor: Christie Ballantyne, M.D.
Study Contact: Anna Tran (713) 798-8800 or


Anna Tran atran@bcm.eduPhone 1: (713) 798-8800
IRB: h-37442




Nov 04, 2015